[go: up one dir, main page]

DK3265575T3 - Cd20-bindende molekyler og anvendelser deraf - Google Patents

Cd20-bindende molekyler og anvendelser deraf Download PDF

Info

Publication number
DK3265575T3
DK3265575T3 DK16759586.7T DK16759586T DK3265575T3 DK 3265575 T3 DK3265575 T3 DK 3265575T3 DK 16759586 T DK16759586 T DK 16759586T DK 3265575 T3 DK3265575 T3 DK 3265575T3
Authority
DK
Denmark
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
DK16759586.7T
Other languages
English (en)
Inventor
Bruce Keyt
Omar Duramad
Fen Zhang
Ramesh Baliga
Beatrice Tien-Yi Wang
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Application granted granted Critical
Publication of DK3265575T3 publication Critical patent/DK3265575T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
DK16759586.7T 2015-03-04 2016-03-04 Cd20-bindende molekyler og anvendelser deraf DK3265575T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562128284P 2015-03-04 2015-03-04
PCT/US2016/020920 WO2016141303A2 (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
DK3265575T3 true DK3265575T3 (da) 2021-05-31

Family

ID=56849117

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16759586.7T DK3265575T3 (da) 2015-03-04 2016-03-04 Cd20-bindende molekyler og anvendelser deraf

Country Status (18)

Country Link
US (2) US10787520B2 (da)
EP (2) EP3265575B1 (da)
JP (3) JP6793655B2 (da)
KR (4) KR20240135877A (da)
CN (2) CN115093479A (da)
AU (3) AU2016226060B2 (da)
BR (1) BR112017018941B8 (da)
CA (1) CA2978324A1 (da)
DK (1) DK3265575T3 (da)
ES (1) ES2874558T3 (da)
HU (1) HUE054642T2 (da)
IL (2) IL297997A (da)
NZ (1) NZ762365A (da)
PL (1) PL3265575T3 (da)
PT (1) PT3265575T (da)
SG (2) SG11201707144VA (da)
SI (1) SI3265575T1 (da)
WO (1) WO2016141303A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
WO2015113005A1 (en) 2014-01-27 2015-07-30 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR20230155600A (ko) 2014-04-03 2023-11-10 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
CA2947048C (en) 2014-06-11 2023-10-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
HUE051013T2 (hu) 2015-01-20 2021-01-28 Igm Biosciences Inc Tumor nekrózis faktor (TNF) szupercsalád receptor kötõ molekulák és ezek alkalmazása
CN108064247B (zh) 2015-02-05 2022-06-03 分子模板公司 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物
CN107921285B (zh) * 2015-03-25 2022-06-07 Igm生物科学股份有限公司 多价乙型肝炎病毒抗原结合分子及其应用
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
IL292708B2 (en) 2015-05-30 2024-08-01 Molecular Templates Inc De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
JP7065766B2 (ja) * 2015-09-30 2022-05-12 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CN114773439A (zh) 2016-12-07 2022-07-22 分子模板公司 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
SG11202008343YA (en) 2018-03-01 2020-09-29 Igm Biosciences Inc IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
AU2019368289A1 (en) * 2018-10-23 2021-04-29 Igm Biosciences, Inc. Multivalent IgM- and IgA-Fc-based binding molecules
AU2020329301A1 (en) 2019-08-15 2022-02-17 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
JP2022549186A (ja) * 2019-09-19 2022-11-24 アイジーエム バイオサイエンシズ インコーポレイテッド 高い標的密度の細胞に対する選択性を向上させた多量体抗体
JP2023522962A (ja) 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド Ｐｄ－１アゴニスト多量体結合分子
WO2022109023A1 (en) * 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN112521508B (zh) * 2020-12-29 2021-08-03 郴州宾泽医学检验有限公司 一种cd20抗体及其治疗癌症的应用
JP2024508709A (ja) * 2021-02-17 2024-02-28 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ１２３結合分子及びその使用法
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6476198B1 (en) * 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
CA2276046A1 (en) * 1997-01-10 1998-07-16 Epicyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
CA2375912C (en) 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CN101643512A (zh) 2000-04-28 2010-02-10 行星生物技术有限公司 预防鼻病毒感染的新型免疫粘附素
EP1328293B1 (en) 2000-05-10 2012-02-15 Signe BioPharma Inc. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7151164B2 (en) 2002-02-14 2006-12-19 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
EP2865688A1 (en) 2002-03-01 2015-04-29 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
CA2481207C (en) 2002-04-12 2015-06-30 Medarex, Inc. Methods of treatment using ctla-4 antibodies
EP1519958B1 (en) 2002-06-14 2014-10-15 Immunomedics, Inc. Humanized monoclonal antibody hpam4
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
KR20090088973A (ko) * 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP1626992B1 (en) 2003-05-23 2010-06-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
ES2358427T3 (es) 2003-10-16 2011-05-10 Micromet Ag Elementos de unión a cd-3 desinmunizados multiespecíficos.
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
DK1814913T3 (da) 2004-11-05 2015-09-28 Univ Leland Stanford Junior Antistofinduceret cellemembranbeskadigelse.
DK3332808T3 (da) 2005-03-03 2020-12-14 Immunomedics Inc Humaniserede L243-antistoffer
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US20110129412A1 (en) * 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
JP5188969B2 (ja) * 2005-08-03 2013-04-24 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド ヒト化免疫グロブリンを発現するトランスジェニック動物におけるｂ細胞アポトーシスの抑制
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CN101426521A (zh) 2005-12-21 2009-05-06 医疗免疫有限责任公司 EPHA2 BiTE分子及其应用
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US20100184959A1 (en) 2007-03-19 2010-07-22 Medimmune Limited Polypeptide Variants
WO2008135963A2 (en) 2007-05-02 2008-11-13 Hemogem Inc. Fibrinogen for treatment of bleeding in trauma and platelet disorders
CN201229536Y (zh) 2008-07-03 2009-04-29 鸿富锦精密工业（深圳）有限公司 电脑机箱
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
CN102918062A (zh) 2010-02-11 2013-02-06 阿雷克森制药公司 使用抗cd200抗体的治疗方法
CN104725507B (zh) 2010-10-19 2018-12-21 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
MX363819B (es) 2012-02-08 2019-04-03 Igm Biosciences Inc Uniones a cdim y sus usos.
CN104349789B (zh) * 2012-04-05 2018-05-04 戈特弗里德·希姆莱 分泌性免疫球蛋白复合物
NZ701278A (en) 2012-04-17 2016-12-23 Mayo Foundation Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
WO2014022592A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
US10167333B2 (en) 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
KR20230155600A (ko) 2014-04-03 2023-11-10 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
HUE051013T2 (hu) 2015-01-20 2021-01-28 Igm Biosciences Inc Tumor nekrózis faktor (TNF) szupercsalád receptor kötõ molekulák és ezek alkalmazása
CN107921285B (zh) 2015-03-25 2022-06-07 Igm生物科学股份有限公司 多价乙型肝炎病毒抗原结合分子及其应用
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. BRIDGE LINKER FOR CONJUGATING CELL BINDING MOLECULES
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
JP7065766B2 (ja) * 2015-09-30 2022-05-12 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
AU2017299610B2 (en) 2016-07-20 2022-09-29 Igm Biosciences, Inc. Multimeric CD40 binding molecules and uses thereof
EP3487533A4 (en) 2016-07-20 2020-03-25 IGM Biosciences, Inc. MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF
CA3030634A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
CN109561681A (zh) 2016-07-20 2019-04-02 Igm生物科学股份有限公司 多聚gitr结合分子及其用途
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111757941A (zh) 2018-02-26 2020-10-09 Igm生物科学股份有限公司 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途
SG11202008343YA (en) 2018-03-01 2020-09-29 Igm Biosciences Inc IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
AU2019368289A1 (en) 2018-10-23 2021-04-29 Igm Biosciences, Inc. Multivalent IgM- and IgA-Fc-based binding molecules

Also Published As

Publication number Publication date
CN115093479A (zh) 2022-09-23
BR112017018941B8 (pt) 2023-01-10
NZ762365A (en) 2024-11-29
PL3265575T3 (pl) 2021-11-29
JP2021036885A (ja) 2021-03-11
KR20170122258A (ko) 2017-11-03
CN107532188A (zh) 2018-01-02
JP2023099206A (ja) 2023-07-11
KR20220018081A (ko) 2022-02-14
PT3265575T (pt) 2021-06-16
SG10202109717TA (en) 2021-10-28
NZ735607A (en) 2024-01-26
EP3265575A4 (en) 2018-08-08
AU2016226060B2 (en) 2020-04-23
EP3957738A1 (en) 2022-02-23
US20210032357A1 (en) 2021-02-04
AU2023203119A1 (en) 2023-06-15
KR20240135877A (ko) 2024-09-12
CA2978324A1 (en) 2016-09-09
JP2018508214A (ja) 2018-03-29
EP3265575A2 (en) 2018-01-10
AU2020202667A1 (en) 2020-05-14
BR112017018941A8 (pt) 2018-06-12
BR112017018941B1 (pt) 2022-03-03
SI3265575T1 (sl) 2021-08-31
IL254223B2 (en) 2023-05-01
EP3265575B1 (en) 2021-04-21
AU2016226060A1 (en) 2017-10-12
CN107532188B (zh) 2022-05-10
KR20230130148A (ko) 2023-09-11
ES2874558T3 (es) 2021-11-05
WO2016141303A2 (en) 2016-09-09
KR102357312B1 (ko) 2022-02-03
IL254223B1 (en) 2023-01-01
IL254223A (en) 2017-10-31
HUE054642T2 (hu) 2021-09-28
SG11201707144VA (en) 2017-09-28
IL297997A (en) 2023-01-01
WO2016141303A3 (en) 2016-11-03
US20190100597A1 (en) 2019-04-04
JP6793655B2 (ja) 2020-12-02
US10787520B2 (en) 2020-09-29
BR112017018941A2 (pt) 2018-04-17

Similar Documents

Publication Publication Date Title
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
IL256416B (en) Multispecific antigen-binding molecules and uses thereof
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
IL263799A (en) Multimeric ox40 binding molecules and uses thereof
HUE054339T2 (hu) CD73-ra specifikus kötõmolekulák és alkalmazásaik
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3380522T5 (da) Antistofmolekyler til april og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
HK1248721A1 (zh) 抗體分子及其用途
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
HK1258317A1 (zh) 對asct2具有特異性的結合分子及其用途
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3303384T3 (da) Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3152305T3 (da) Prolinspecifik endoprotease og anvendelse deraf
DK3245219T3 (da) Glypicanepitoper og anvendelser deraf
DK3283571T3 (da) Klart bindemiddel og anvendelser deraf